

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS **WEIGHT LOSS MANAGEMENT**

BRAND NAME
(generic)

XENICAL
(orlistat)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Xenical is also indicated to reduce the risk for weight regain after prior weight loss. Xenical is indicated for obese patients with an initial body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has completed at least 6 months of therapy with the requested drug
AND
 - The patient lost at least 5 percent of baseline bodyweight OR the patient has continued to maintain their initial 5 percent weight loss. Documentation is required for approval.

OR

- The requested drug will be used with a reduced calorie diet and increased physical activity for chronic weight management
AND
 - The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy
AND
 - The patient has a body mass index (BMI) greater than or equal to 30 kilogram per square meter
OR
 - The patient has a body mass index (BMI) greater than or equal to 27 kilogram per square meter AND has at least one weight related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia)

REFERENCES

1. Xenical [package insert]. Montgomery, AL: H2-Pharma, LLC; January 2018.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, Ohio: UpToDate, Inc.; 2021; Accessed June 28, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/>. Accessed June 28, 2021.
4. National Heart, Lung, and Blood Institute. Goals of Weight Management/Treatment to Prevent Further Weight Gain. <https://www.nhlbi.nih.gov/health/educational/wecan/portion/documents/CORESET3>. Accessed June 28, 2021.
5. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute. NIH Publication No. 12-7486. October 2012. http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf. 141-159. Accessed June 28, 2021.
6. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 2, 1 February 2015, Pages 342–362. <https://academic.oup.com/jcem/article/100/2/342/2813109>. Accessed June 28, 2021.

7. Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2013; 129:S102–S138.
8. Torgerson JS, Boldrin MN, Hauptman J, et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004; 27:155-161.